With Covid -19 lashing out a population 7.8 billion, the news of Moderna claiming covid vaccine more than 94% efficient bought relief to our anxieties.
Second, in line, Moderna on Monday announced its further course of seeking emergency use authorization from the U.S Food and Drug Administration (FDA). It also plans to file similar permission with the European Medicines Agency.
The Moderna covid vaccine underwent its Phase 3 clinical trial and showed a convincing result of 94.1% efficiency on Covid patients.
As per the analysis report released by modern, out of 30,000 participants, 196 tested positive for Covid. The participants also had some elderly people who dare declared to be easy prey for the virus.
The study was taken forward by dividing 196 confirmed cases into two groups. The group of 185 was observed in the placebo group while the remaining 11 got the two-dose vaccine. This made Moderna covid vaccine 94% efficient
“This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease and our covid vaccine is 94% efficient and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death,” Moderna CEO Stephane Bancel asserted.
What does emergency use authorization mean?
Unlike the full approval of a vaccine, emergency use authorization allows some adult patients to receive the vaccine with the process of development still in the pipeline.
This shall allow the firms who get a green signal for the same to start manufacturing some vials of Moderna covid vaccine shots so that it can be put to use in controlled numbers.
Pfizer and BioNTech’s vaccine was the first one to get permission for emergency use on November 20, after it divulged its report of effectiveness. This gave them an edge and upper hand in the competition.
How does the Moderna covid vaccine work?
An mRNA vaccine, Moderna’s solution extends genetic instructions to the body to create its impactful antibodies that prevent receptor sites (a particular component on cell’s surface that can react with a molecule like a virus) from infecting the body with Covid.
It is a novel therapeutic approach that has more potential to fight the virus than a person’s natural antibodies.
Moderna covid vaccine which is claimed to be 94% efficient, that as co-developed with the US National Institutes of Health, works across all race type, age groups and gender. In the report released of testing on 196 patients, 33 were those who belonged to the age group of above 65, 42 from Hispanic, Black, Latino and other various communities.
No significant side effect was observed apart from common reactions like fatigue, muscle pain, headache, pain on injected point etc. Else it was well tolerated among the patients.
Moderna shares shot up after the covid vaccine news
Moderna informed, in October, the investors that it is “actively preparing” for the launch on a global scale of its covid vaccine that had the potential to combat the virus.
When the news hit the ground, the shares of Moderna sour more than 12% in premarket trading.CEO Stephane Bancel called it a “game-changer” and “pivotal moment”.
He told “Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matter.
This positive interim analysis from our Phase 3 study has given us the first clinical validation that Moderna covid vaccine can prevent COVID-19 disease, including severe disease.”
Among the three front runner ups namely, Moderna, Pfizer and AstraZeneca, AstraZeneca jab is the cheapest. Also unlike the other two, it does not require storage in ultra-low temperatures. Moderna informed that the vaccine can be stored at 36-36 degrees Fahrenheit for up to 30 days while for Pfizer, its vaccine requires minus 94 degrees Fahrenheit.
But the effectiveness of AstraZeneca lies in range 62-90% which is lower than the other two. AstraZeneca is not likely to apply for authorization in the U.S until another round of final testing.
With many other companies and organization still working on developing the vaccine, the advancement made had bought a wave of hope among the masses. The race for maximum market share continues among vaccine developers.
The world has now lost 1.47 million people to corona but the virus has touched the lives of every single being. The numbers of patients infected are still on the count and the only tool that can help the world overcome the challenge and uproot the virus is a vaccine.